These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39349269)

  • 1. Tyrosine kinase 2 inhibitors in autoimmune diseases.
    Ramakrishna C; Mason A; Edwards CJ
    Autoimmun Rev; 2024 Sep; 23(11):103649. PubMed ID: 39349269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
    Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
    Huang MY; Armstrong AW
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TYK2: an emerging therapeutic target in rheumatic disease.
    Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
    Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
    Fang Z; Sun H; Wang Y; Sun Z; Yin M
    Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
    Rusiñol L; Puig L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
    Krueger JG; McInnes IB; Blauvelt A
    J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
    Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
    J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
    Jensen LT; Attfield KE; Feldmann M; Fugger L
    EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition.
    Nikolopoulos D; Parodis I
    Front Med (Lausanne); 2023; 10():1217147. PubMed ID: 37457579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
    Zhang K; Ye K; Tang H; Qi Z; Wang T; Mao J; Zhang X; Jiang S
    J Med Chem; 2023 Apr; 66(7):4378-4416. PubMed ID: 36951608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
    Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
    J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
    Gonciarz M; Pawlak-Buś K; Leszczyński P; Owczarek W
    Immunotherapy; 2021 Sep; 13(13):1135-1150. PubMed ID: 34235974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
    Gonzalez Lopez de Turiso F; Guckian K
    Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deucravacitinib in moderate-to-severe psoriasis.
    Vu A; Maloney V; Gordon KB
    Immunotherapy; 2022 Nov; 14(16):1279-1290. PubMed ID: 36373503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
    Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2021 Nov; 27(12):2023-2030. PubMed ID: 34089259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.
    Martin G
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):417-435. PubMed ID: 36592300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.